Oncology — Total Revenue
Guardant Health Oncology — Total Revenue increased by 7.9% to $204.95M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 36.1%, from $150.56M to $204.95M. Over 2 years (FY 2023 to FY 2025), Oncology — Total Revenue shows an upward trend with a 30.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates growing clinical adoption, expanded insurance coverage, or successful commercialization of new diagnostic panels, while a decrease may signal competitive pressure or reduced testing volumes.
Detailed definition
This metric represents the total gross income generated from the sale of liquid biopsy tests, companion diagnostics, and...
Peer comparison
Comparable to revenue reported by other molecular diagnostics and precision medicine companies focused on oncology, often benchmarked against total test volume and average selling price per test.
gh_segment_oncology_total_revenueHistorical Data
| Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $100.97M | $100.97M | $100.97M | $100.97M | $125.75M | $130.27M | $141.20M | $145.61M | $150.56M | $158.69M | $184.40M | $189.95M | $204.95M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +24.5% | +3.6% | +8.4% | +3.1% | +3.4% | +5.4% | +16.2% | +3.0% | +7.9% |
| YoY Change | — | — | — | — | +24.5% | +29.0% | +39.8% | +44.2% | +19.7% | +21.8% | +30.6% | +30.4% | +36.1% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Guardant Health's oncology — total revenue?
- Guardant Health (GH) reported oncology — total revenue of $204.95M in Q1 2026.
- How has Guardant Health's oncology — total revenue changed year-over-year?
- Guardant Health's oncology — total revenue increased by 36.1% year-over-year, from $150.56M to $204.95M.
- What is the long-term trend for Guardant Health's oncology — total revenue?
- Over 2 years (2023 to 2025), Guardant Health's oncology — total revenue has grown at a 30.1% compound annual growth rate (CAGR), from $403.88M to $683.60M.
- What does oncology — total revenue mean?
- The total amount of money earned from the company's cancer testing products and services.